{"entity":{"id":"nct05329532","kind":"trial","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma, run by Scancell Ltd, now recruiting.","summary":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer is a phase 1/2 interventional study registered as NCT05329532 by Scancell Ltd, with 168 participants planned, started 2022-04-07 and due to reach its primary completion in 2026-07-01. Interventions recorded: Modi-1 Moditope, Pembrolizumab and MicronJet600™ microneedle device (NanoPass).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05329532","url":"https://clinicaltrials.gov/study/NCT05329532"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","rcc","ovarian","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["scancell"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05329532","phase":"1/2","setting":"A Phase 1/2, Multicentre, Open-Label Study of Modi-1 Moditope in Patients With Breast, Head and Neck, Ovarian, or Renal Cancer","sponsor":"Scancell Ltd","enrolled":168,"outcomes":[]},"route":"/trials/nct05329532/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/"}]}}